Liver alkaline phosphatase: A missing link between choleresis and biliary inflammation

Hepatology

Volumn 61, Issue 6, 2015, Pages 2080-2090

  Poupon, Raoul ^a,b  

^a SORBONNE UNIVERSITÉ   (France)

^b HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE RECEPTOR; ADENOSINE TRIPHOSPHATE; ALKALINE PHOSPHATASE; ASIALOGLYCOPROTEIN RECEPTOR; BILIRUBIN; BUDESONIDE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; ECTO 5' NUCLEOTIDASE; G PROTEIN COUPLED RECEPTOR; LIPOPOLYSACCHARIDE; PHOSPHOLIPASE C; PHOSPHOLIPASE D; PURINERGIC P2 RECEPTOR; CHOLAGOGUE; URSODEOXYCHOLIC ACID;

ALKALINE PHOSPHATASE BLOOD LEVEL; ALKALINITY; ANTIINFLAMMATORY ACTIVITY; APICAL MEMBRANE; ARTICLE; BILE ALKALINITY; BILE FLOW; BILIARY TRACT FIBROSIS; CELL DIFFERENTIATION; CELL POLARITY; CLINICAL PRACTICE; CYTOKINE PRODUCTION; DISEASE SEVERITY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME RELEASE; EXTRAHEPATIC BILE DUCT OBSTRUCTION; HUMAN; LIVER CELL; PATHOPHYSIOLOGY; PORTAL VEIN BLOOD FLOW; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; TH17 CELL; TRANS GOLGI NETWORK; ANIMAL; BILE; CHEMISTRY; CHOLANGITIS, SCLEROSING; ENZYMOLOGY; INFECTION; LIVER; LIVER CIRRHOSIS, BILIARY; METABOLISM; SECRETION (PROCESS);

ADENOSINE TRIPHOSPHATE; ALKALINE PHOSPHATASE; ANIMALS; BILE; CHOLAGOGUES AND CHOLERETICS; CHOLANGITIS, SCLEROSING; HUMANS; INFECTION; LIVER; LIVER CIRRHOSIS, BILIARY; URSODEOXYCHOLIC ACID;

EID: 84929607639     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27715     Document Type: Article

References (119)

1. Lammers WJ, van Buuren HR, Hirschfield GM, Janssen HL, Invernizzi P, Mason AL, et al. Levels of alkaline phosphatase and bilirubin are surrogate endpoints of outcomes of patients with primary biliary cirrhosis: an international follow-up study. Gastroenterology 2014;147:1338-1349.
2. Willamson KD, Chapman RW. Editorial: Further evidence for the role of serum alkaline phosphatase as a useful surrogate marker of prognosis in PSC. Aliment Pharmacol Ther 2015;41:149-151.
3. Beuers U, Hohenester S, de Buy Wenniger LJ, Kremer AE, Jansen PL, Elferink RP. The biliary HCO3- umbrella: a unifying hypothesis on pathogenetic and therapeutic aspects of fibrosing cholangiopathies. Hepatology 2010;52:1489-1496.
4. Hohenester S, Wenniger LM, Paulusma CC, van Vliet SJ, Jefferson DM, Elferink RP, et al. A biliary HCO3- umbrella constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes. Hepatology 2012;55:173-183.
5. Harris H. The human alkaline phosphatases: what we know and what we don't know. Clin Chim Acta 1990;186:133-150.
6. Fishman WH. Alkaline phosphatase isozymes: recent progress. Clin Biochem 1990;23:99-104.
7. Hoylaerts MF, Manes T, Millan JL. Mammalian alkaline phosphatases are allosteric enzymes. J Biol Chem 1997;272:22781-22787.
8. Millan JL. Alkaline phosphatases: structure, substrate specificity and functional relatedness to other members of a large superfamily of enzymes. Purinergic Signal 2006;2:335-341.
9. Zimmermann H, Zebisch M, Strater N. Cellular function and molecular structure of ecto-nucleotidases. Purinergic Signal 2012;8:437-502.
10. Lalles JP. Intestinal alkaline phosphatase: multiple biological roles in maintenance of intestinal homeostasis and modulation by diet. Nutr Rev 2010;68:323-332.
11. Chen KT, Malo MS, Moss AK, Zeller S, Johnson P, Ebrahimi F, et al. Identification of specific targets for the gut mucosal defense factor intestinal alkaline phosphatase. Am J Physiol Gastrointest Liver Physiol 2010;299:G467-G475.
12. Ait-Slimane T, Galmes R, Trugnan G, Maurice M. Basolateral internalization of GPI-anchored proteins occurs via a clathrin-independent flotillin-dependent pathway in polarized hepatic cells. Mol Biol Cell 2009;20:3792-3800.
13. Low MG, Huang KS. Factors affecting the ability of glycosylphosphatidylinositol-specific phospholipase D to degrade the membrane anchors of cell surface proteins. Biochem J 1991;279(Pt 2):483-493.
14. Van Hoof VO, De Broe ME. Interpretation and clinical significance of alkaline phosphatase isoenzyme patterns. Crit Rev Clin Lab Sci 1994;31:197-293.
15. Deng JT, Hoylaerts MF, De Broe ME, van Hoof VO. Hydrolysis of membrane-bound liver alkaline phosphatase by GPI-PLD requires bile salts. Am J Physiol 1996;271:G655-G663.
16. Young GP, Rose IS, Cropper S, Seetharam S, Alpers DH. Hepatic clearance of rat plasma intestinal alkaline phosphatase. Am J Physiol 1984;247:G419-G426.
17. Blom E, Ali MM, Mortensen B, Huseby NE. Elimination of alkaline phosphatases from circulation by the galactose receptor. Different isoforms are cleared at various rates. Clin Chim Acta 1998;270:125-137.
18. Meijer DK, Scholtens HB, Hardonk MJ. The role of the liver in clearance of glycoproteins from the general circulation, with special reference to intestinal alkaline phosphatase. Pharm Weekbl Sci 1982;4:57-70.
19. Russel FG, Weitering JG, Oosting R, Groothuis GM, Hardonk MJ, Meijer DK. Influence of taurocholate on hepatic clearance and biliary excretion of asialo intestinal alkaline phosphatase in the rat in vivo and in isolated perfused rat liver. Gastroenterology 1983;85:225-234.
20. Warnes TW, Hine P, Kay G, Smith A. Intestinal alkaline phosphatase in bile: evidence for an enterohepatic circulation. Gut 1981;22:493-498.
21. Alvaro D, Benedetti A, Marucci L, Delle Monache M, Monterubbianesi R, Di Cosimo E, et al. The function of alkaline phosphatase in the liver: regulation of intrahepatic biliary epithelium secretory activities in the rat. Hepatology 2000;32:174-184.
22. Tuin A, Huizinga-Van der Vlag A, van Loenen-Weemaes AM, Meijer DK, Poelstra K. On the role and fate of LPS-dephosphorylating activity in the rat liver. Am J Physiol Gastrointest Liver Physiol 2006;290:G377-G385.
23. Kats S, Brands R, Hamad MA, Seinen W, Scharnhorst V, Wulkan RW, et al. Prophylactic treatment with alkaline phosphatase in cardiac surgery induces endogenous alkaline phosphatase release. Int J Artif Organs 2012;35:144-151.
24. Chambers JC, Zhang W, Sehmi J, Li X, Wass MN, Van der Harst P, et al. Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma. Nat Genet 2011;43:1131-1138.
25. Yuan X, Waterworth D, Perry JR, Lim N, Song K, Chambers JC, et al. Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes. Am J Hum Genet 2008;83:520-528.
26. Sotil EU, Jensen DM. Serum enzymes associated with cholestasis. Clin Liver Dis 2004;8:41-54, vi.
27. Pike AF, Kramer NI, Blaauboer BJ, Seinen W, Brands R. A novel hypothesis for an alkaline phosphatase "rescue" mechanism in the hepatic acute phase immune response. Biochim Biophys Acta 2013;1832:2044-2056.
28. Webber M, Krishnan A, Thomas NG, Cheung BM. Association between serum alkaline phosphatase and C-reactive protein in the United States National Health and Nutrition Examination Survey 2005-2006. Clin Chem Lab Med 2010;48:167-173.
29. Kellett KA, Williams J, Vardy ER, Smith AD, Hooper NM. Plasma alkaline phosphatase is elevated in Alzheimer's disease and inversely correlates with cognitive function. Int J Mol Epidemiol Genet 2011;2:114-121.
30. Kunutsor SK, Apekey TA, Seddoh D, Walley J. Liver enzymes and risk of all-cause mortality in general populations: a systematic review and meta-analysis. Int J Epidemiol 2014;43:187-201.
31. Shinozaki T, Watanabe H, Takagishi K, Pritzker KP. Allotype immunoglobulin enhances alkaline phosphatase activity: implications for the inflammatory response. J Lab Clin Med 1998;132:320-328.
32. Kaplan MM, Righetti A. Induction of rat liver alkaline phosphatase: the mechanism of the serum elevation in bile duct obstruction. J Clin Invest 1970;49:508-516.
33. Khan KN, Tsutsumi T, Nakata K, Nakao K, Kato Y, Nagataki S. Regulation of alkaline phosphatase gene expression in human hepatoma cells by bile acids. J Gastroenterol Hepatol 1998;13:643-650.
34. Post SM, Duez H, Gervois PP, Staels B, Kuipers F, Princen HM. Fibrates suppress bile acid synthesis via peroxisome proliferator-activated receptor-alpha-mediated downregulation of cholesterol 7alpha-hydroxylase and sterol 27-hydroxylase expression. Arterioscler Thromb Vasc Biol 2001;21:1840-1845.
35. Stahlberg D, Reihner E, Rudling M, Berglund L, Einarsson K, Angelin B. Influence of bezafibrate on hepatic cholesterol metabolism in gallstone patients: reduced activity of cholesterol 7 alpha-hydroxylase. Hepatology 1995;21:1025-1030.
36. Hatoff DE, Hardison WG. Bile acid-dependent secretion of alkaline phosphatase in rat bile. Hepatology 1982;2:433-439.
37. Ogawa H, Mink J, Hardison WG, Miyai K. Alkaline phosphatase activity in hepatic tissue and serum correlates with amount and type of bile acid load. Lab Invest 1990;62:87-95.
38. Accatino L, Pizarro M, Solis N, Koenig CS. Association of canalicular membrane enzymes with bile acid micelles and lipid aggregates in human and rat bile. Biochim Biophys Acta 1995;1243:33-42.
39. Jorgensen RA, Dickson ER, Hofmann AF, Rossi SS, Lindor KD. Characterisation of patients with a complete biochemical response to ursodeoxycholic acid. Gut 1995;36:935-938.
40. Leuschner M, Dietrich CF, You T, Seidl C, Raedle J, Herrmann G, et al. Characterisation of patients with primary biliary cirrhosis responding to long term ursodeoxycholic acid treatment. Gut 2000;46:121-126.
41. Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology 2006;130:715-720.
42. Corpechot C, Abenavoli L, Rabahi N, Chretien Y, Andreani T, Johanet C, et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 2008;48:871-877.
43. Kumagi T, Guindi M, Fischer SE, Arenovich T, Abdalian R, Coltescu C, et al. Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis. Am J Gastroenterol 2010;105:2186-2194.
44. Fitz JG. Regulation of cellular ATP release. Trans Am Clin Climatol Assoc 2007;118:199-208.
45. Tabibian JH, Masyuk AI, Masyuk TV, O'Hara SP, LaRusso NF. Physiology of cholangiocytes. Compr Physiol 2013;3:541-565.
46. Burnstock G, Vaughn B, Robson SC. Purinergic signalling in the liver in health and disease. Purinergic Signal 2014;10:51-70.
47. Schlosser SF, Burgstahler AD, Nathanson MH. Isolated rat hepatocytes can signal to other hepatocytes and bile duct cells by release of nucleotides. Proc Natl Acad Sci USA 1996;93:9948-9953.
48. Dranoff JA, Masyuk AI, Kruglov EA, LaRusso NF, Nathanson MH. Polarized expression and function of P2Y ATP receptors in rat bile duct epithelia. Am J Physiol Gastrointest Liver Physiol 2001;281:G1059-G1067.
49. Minagawa N, Nagata J, Shibao K, Masyuk AI, Gomes DA, Rodrigues MA, et al. Cyclic AMP regulates bicarbonate secretion in cholangiocytes through release of ATP into bile. Gastroenterology 2007;133:1592-1602.
50. Fiorotto R, Spirli C, Fabris L, Cadamuro M, Okolicsanyi L, Strazzabosco M. Ursodeoxycholic acid stimulates cholangiocyte fluid secretion in mice via CFTR-dependent ATP secretion. Gastroenterology 2007;133:1603-1613.
51. Nathanson MH, Burgstahler AD, Masyuk A, Larusso NF. Stimulation of ATP secretion in the liver by therapeutic bile acids. Biochem J 2001;358:1-5.
52. Mizumori M, Ham M, Guth PH, Engel E, Kaunitz JD, Akiba Y. Intestinal alkaline phosphatase regulates protective surface microclimate pH in rat duodenum. J Physiol 2009;587:3651-3663.
53. Pezzulo AA, Tang XX, Hoegger MJ, Alaiwa MH, Ramachandran S, Moninger TO, et al. Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung. Nature 2012;487:109-113.
54. Fausther M, Lecka J, Kukulski F, Levesque SA, Pelletier J, Zimmermann H, et al. Cloning, purification, and identification of the liver canalicular ecto-ATPase as NTPDase8. Am J Physiol Gastrointest Liver Physiol 2007;292:G785-G795.
55. Zsembery A, Spirli C, Granato A, LaRusso NF, Okolicsanyi L, Crepaldi G, et al. Purinergic regulation of acid/base transport in human and rat biliary epithelial cell lines. Hepatology 1998;28:914-920.
56. + exchanger activities in primary biliary cirrhosis. Hepatology 2002;35:1513-1521.
57. Shibao K, Hirata K, Robert ME, Nathanson MH. Loss of inositol 1, 4, 5-trisphosphate receptors from bile duct epithelia is a common event in cholestasis. Gastroenterology 2003;125:1175-1187.
58. Spirli C, Nathanson MH, Fiorotto R, Duner E, Denson LA, Sanz JM, et al. Proinflammatory cytokines inhibit secretion in rat bile duct epithelium. Gastroenterology 2001;121:156-169.
59. Spirli C, Fabris L, Duner E, Fiorotto R, Ballardini G, Roskams T, et al. Cytokine-stimulated nitric oxide production inhibits adenylyl cyclase and cAMP-dependent secretion in cholangiocytes. Gastroenterology 2003;124:737-753.
60. Prieto J, Garcia N, Marti-Climent JM, Penuelas I, Richter JA, Medina JF. Assessment of biliary bicarbonate secretion in humans by positron emission tomography. Gastroenterology 1999;117:167-172.
61. 2+-ecto-ATPase in estrogen-induced and obstructive cholestasis in the rat. J Lab Clin Med 2000;136:125-137.
62. Stieger B, Meier PJ, Landmann L. Effect of obstructive cholestasis on membrane traffic and domain-specific expression of plasma membrane proteins in rat liver parenchymal cells. Hepatology 1994;20:201-212.
63. Zinchuk VS, Okada T, Seguchi H. Lipopolysaccharide alters ecto-ATP-diphosphohydrolase and causes relocation of its reaction product in experimental intrahepatic cholestasis. Cell Tissue Res 2001;304:103-109.
64. Solle M, Labasi J, Perregaux DG, Stam E, Petrushova N, Koller BH, et al. Altered cytokine production in mice lacking P2X(7) receptors. J Biol Chem 2001;276:125-132.
65. Labasi JM, Petrushova N, Donovan C, McCurdy S, Lira P, Payette MM, et al. Absence of the P2X7 receptor alters leukocyte function and attenuates an inflammatory response. J Immunol 2002;168:6436-6445.
66. Le Feuvre R, Brough D, Rothwell N. Extracellular ATP and P2X7 receptors in neurodegeneration. Eur J Pharmacol 2002;447:261-269.
67. Elliott JI, Higgins CF. Major histocompatibility complex class I shedding and programmed cell death stimulated through the proinflammatory P2X7 receptor: a candidate susceptibility gene for NOD diabetes. Diabetes 2004;53:2012-2017.
68. Humphreys BD, Dubyak GR. Induction of the P2z/P2X7 nucleotide receptor and associated phospholipase D activity by lipopolysaccharide and IFN-gamma in the human THP-1 monocytic cell line. J Immunol 1996;157:5627-5637.
69. Humphreys BD, Dubyak GR. Modulation of P2X7 nucleotide receptor expression by pro- and anti-inflammatory stimuli in THP-1 monocytes. J Leukoc Biol 1998;64:265-273.
70. Lemaire I, Leduc N. Purinergic P2X7 receptor function in lung alveolar macrophages: pharmacologic characterization and bidirectional regulation by Th1 and Th2 cytokines. Drug Dev Res 2003;59:118-127.
71. Bours MJ, Swennen EL, Di Virgilio F, Cronstein BN, Dagnelie PC. Adenosine 5'-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacol Ther 2006;112:358-404.
72. Idzko M, Ferrari D, Eltzschig HK. Nucleotide signalling during inflammation. Nature 2014;509:310-317.
73. Trautmann A. Extracellular ATP in the immune system: more than just a "danger signal." Sci Signal 2009;2:pe6.
74. Atarashi K, Nishimura J, Shima T, Umesaki Y, Yamamoto M, Onoue M, et al. ATP drives lamina propria T(H)17 cell differentiation. Nature 2008;455:808-812.
75. Kondo M, Murakawa Y, Harashima N, Kobayashi S, Yamaguchi S, Harada M. Roles of proinflammatory cytokines and the Fas/Fas ligand interaction in the pathogenesis of inflammatory myopathies. Immunology 2009;128:e589-e599.
76. Hopf U, Moller B, Stemerowicz R, Lobeck H, Rodloff A, Freudenberg M, et al. Relation between Escherichia coli R(rough)-forms in gut, lipid A in liver, and primary biliary cirrhosis. Lancet 1989;2:1419-1422.
77. Stemerowicz R, Hopf U, Moller B, Wittenbrink C, Rodloff A, Reinhardt R, et al. Are antimitochondrial antibodies in primary biliary cirrhosis induced by R(rough)-mutants of enterobacteriaceae? Lancet 1988;2:1166-1170.
78. Harada K, Nakanuma Y. Biliary innate immunity: function and modulation. Mediators Inflamm 2010;2010.
79. Sasatomi K, Noguchi K, Sakisaka S, Sata M, Tanikawa K. Abnormal accumulation of endotoxin in biliary epithelial cells in primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol 1998;29:409-416.
80. Ballot E, Bandin O, Chazouilleres O, Johanet C, Poupon R. Immune response to lipopolysaccharide in primary biliary cirrhosis and autoimmune diseases. J Autoimmun 2004;22:153-158.
81. Trivedi PJ, Adams DH. Mucosal immunity in liver autoimmunity: a comprehensive review. J Autoimmun 2013;46:97-111.
82. Fang C, Yoon S, Tindberg N, Jarvelainen HA, Lindros KO, Ingelman-Sundberg M. Hepatic expression of multiple acute phase proteins and down-regulation of nuclear receptors after acute endotoxin exposure. Biochem Pharmacol 2004;67:1389-1397.
83. Elferink MG, Olinga P, Draaisma AL, Merema MT, Faber KN, Slooff MJ, et al. LPS-induced downregulation of MRP2 and BSEP in human liver is due to a posttranscriptional process. Am J Physiol Gastrointest Liver Physiol 2004;287:G1008-G1016.
84. O'Hara SP, Splinter PL, Trussoni CE, Gajdos GB, Lineswala PN, LaRusso NF. Cholangiocyte N-Ras protein mediates lipopolysaccharide-induced interleukin 6 secretion and proliferation. J Biol Chem 2011;286:30352-30360.
85. Syal G, Fausther M, Dranoff JA. Advances in cholangiocyte immunobiology. Am J Physiol Gastrointest Liver Physiol 2012;303:G1077-G1086.
86. Han X, Fink MP, Uchiyama T, Yang R, Delude RL. Increased iNOS activity is essential for hepatic epithelial tight junction dysfunction in endotoxemic mice. Am J Physiol Gastrointest Liver Physiol 2004;286:G126-G136.
87. Tabibian JH, O'Hara SP, Splinter PL, Trussoni CE, LaRusso NF. Cholangiocyte senescence by way of N-ras activation is a characteristic of primary sclerosing cholangitis. Hepatology 2014;59:2263-2275.
88. Poelstra K, Bakker WW, Klok PA, Hardonk MJ, Meijer DK. A physiologic function for alkaline phosphatase: endotoxin detoxification. Lab Invest 1997;76:319-327.
89. Poelstra K, Bakker WW, Klok PA, Kamps JA, Hardonk MJ, Meijer DK. Dephosphorylation of endotoxin by alkaline phosphatase in vivo. Am J Pathol 1997;151:1163-1169.
90. Koyama I, Matsunaga T, Harada T, Hokari S, Komoda T. Alkaline phosphatases reduce toxicity of lipopolysaccharides in vivo and in vitro through dephosphorylation. Clin Biochem 2002;35:455-461.
91. Bentala H, Verweij WR, Huizinga-Van der Vlag A, van Loenen-Weemaes AM, Meijer DK, Poelstra K. Removal of phosphate from lipid A as a strategy to detoxify lipopolysaccharide. Shock 2002;18:561-566.
92. Chilton PM, Embry CA, Mitchell TC. Effects of differences in lipid A structure on TLR4 pro-inflammatory signaling and inflammasome activation. Front Immunol 2012;3:154.
93. Poupon R. Primary biliary cirrhosis: a 2010 update. J Hepatol 2010;52:745-758.
94. Poupon R. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action. Clin Res Hepatol Gastroenterol 2012;36(Suppl. 1):S3-S12.
95. Beuers U, Boyer JL, Paumgartner G. Ursodeoxycholic acid in cholestasis: potential mechanisms of action and therapeutic applications. Hepatology 1998;28:1449-1453.
96. Allen K, Jaeschke H, Copple BL. Bile acids induce inflammatory genes in hepatocytes: a novel mechanism of inflammation during obstructive cholestasis. Am J Pathol 2011;178:175-186.
97. O'Brien KM, Allen KM, Rockwell CE, Towery K, Luyendyk JP, Copple BL. IL-17A synergistically enhances bile acid-induced inflammation during obstructive cholestasis. Am J Pathol 2013;183:1498-1507.
98. Modica S, Petruzzelli M, Bellafante E, Murzilli S, Salvatore L, Celli N, et al. Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis. Gastroenterology 2012;142:355-365.
99. -/-) mouse cholangiopathy model by promoting biliary HCO3- output. Hepatology 2011;54:1303-1312.
100. Honda A, Ikegami T, Nakamuta M, Miyazaki T, Iwamoto J, Hirayama T, et al. Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid. Hepatology 2013;57:1931-1941.
101. El-Sisi A, Hegazy S, El-Khateeb E. Effects of three different fibrates on intrahepatic cholestasis experimentally induced in rats. PPAR Res 2013;2013:781348.
102. Cindoruk M, Kerem M, Karakan T, Salman B, Akin O, Alper M, et al. Peroxisome proliferator-activated alpha agonist treatment ameliorates hepatic damage in rats with obstructive jaundice: an experimental study. BMC Gastroenterol 2007;7:44.
103. Leuenberger N, Pradervand S, Wahli W. Sumoylated PPARalpha mediates sex-specific gene repression and protects the liver from estrogen-induced toxicity in mice. J Clin Invest 2009;119:3138-3148.
104. He H, Mennone A, Boyer JL, Cai SY. Combination of retinoic acid and ursodeoxycholic acid attenuates liver injury in bile duct-ligated rats and human hepatic cells. Hepatology 2011;53:548-557.
105. -/- mice. J Pharmacol Exp Ther 2014;349:94-98.
106. Swennen EL, Bast A, Dagnelie PC. Immunoregulatory effects of adenosine 5'-triphosphate on cytokine release from stimulated whole blood. Eur J Immunol 2005;35:852-858.
107. Eltzschig HK, Sitkovsky MV, Robson SC. Purinergic signaling during inflammation. N Engl J Med 2012;367:2322-2333.
108. Chen JF, Eltzschig HK, Fredholm BB. Adenosine receptors as drug targets-what are the challenges? Nat Rev Drug Discov 2013;12:265-286.
109. -/- mice. Hepatology 2009;49:1972-1981.
110. Fickert P, Pollheimer MJ, Silbert D, Moustafa T, Halilbasic E, Krones E, et al. Differential effects of norUDCA and UDCA in obstructive cholestasis in mice. J Hepatol 2013;58:1201-1208.
111. Alvaro D, Gigliozzi A, Marucci L, Alpini G, Barbaro B, Monterubbianesi R, et al. Corticosteroids modulate the secretory processes of the rat intrahepatic biliary epithelium. Gastroenterology 2002;122:1058-1069.
112. Arenas F, Hervias I, Uriz M, Joplin R, Prieto J, Medina JF. Combination of ursodeoxycholic acid and glucocorticoids upregulates the AE2 alternate promoter in human liver cells. J Clin Invest 2008;118:695-709.
113. Leuschner M, Maier KP, Schlichting J, Strahl S, Herrmann G, Dahm HH, et al. Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial. Gastroenterology 1999;117:918-925.
114. Rautiainen H, Karkkainen P, Karvonen AL, Nurmi H, Pikkarainen P, Nuutinen H, et al. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial. Hepatology 2005;41:747-752.
115. Rabahi N, Chretien Y, Gaouar F, Wendum D, Serfaty L, Chazouilleres O, et al. Triple therapy with ursodeoxycholic acid, budesonide and mycophenolate mofetil in patients with features of severe primary biliary cirrhosis not responding to ursodeoxycholic acid alone. Gastroenterol Clin Biol 2010;34:283-287.
116. Lalles JP. Intestinal alkaline phosphatase: novel functions and protective effects. Nutr Rev 2014;72:82-94.
117. Kaliannan K, Hamarneh SR, Economopoulos KP, Nasrin Alam S, Moaven O, Patel P, et al. Intestinal alkaline phosphatase prevents metabolic syndrome in mice. Proc Natl Acad Sci USA 2013;110:7003-7008.
118. Malo MS, Moaven O, Muhammad N, Biswas B, Alam SN, Economopoulos KP, et al. Intestinal alkaline phosphatase promotes gut bacterial growth by reducing the concentration of luminal nucleotide triphosphates. Am J Physiol Gastrointest Liver Physiol 2014;306:G826-G838.
119. Fickert P, Pollheimer MJ, Beuers U, Lackner C, Hirschfield G, Housset C, et al. Characterization of animal models for primary sclerosing cholangitis (PSC). J Hepatol 2014;60:1290-1303.